The potency of substituted benzimidazoles such as E3810, omeprazole, RO 18-5364 to inhibit gastric H+,K+-ATPase is correlated with the rate of acid-activation of the inhibitor

This publication has 25 references indexed in Scilit:

• The specificity of omeprazole as an (H++K+)-ATPase inhibitor depends upon the means of its activation
  Biochemical Pharmacology, 1987
• Inhibition of (H+ + K+)-ATPase by omeprazole in isolated gastric vesicles requires proton transport
  Biochimica et Biophysica Acta (BBA) - Biomembranes, 1987
• Inhibition of gastric K+/H+-ATPase by acid-activated 2-((2-pyridylmethyl)sulphinyl) benzimidazole products
  European Journal of Pharmacology, 1987
• The mechanism of action of the antisecretory agent omeprazole
  Journal of Medicinal Chemistry, 1986
• Histamine and duodenal ulcer: effect of omeprazole on gastric histamine in patients with duodenal ulcer.
  Gut, 1986
• Acid activation of (H ⁺ –K ⁺ )-ATPase inhibiting 2-(2-pyridylmethyl-sulphinyl)benzimidazoles: isolation and characterization of the thiophilic ‘active principle’ and its reactions
  Journal of the Chemical Society, Chemical Communications, 1986
• Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats
  Digestive Diseases and Sciences, 1984
• Omeprazole in Zollinger–Ellison Syndrome
  New England Journal of Medicine, 1984
• Effect of substituted benzimidazoles on acid secretion in isolated and enriched guinea pig parietal cells.
  Gut, 1983
• Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.
  Gut, 1983